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Abstract Changes in the content of fructose-2,6-bisphosphate,
a modulator of glycolytic flux, also affect other metabolic fluxes
such as the non-oxidative pentose phosphate pathway. Since this
is the main source of precursors for biosynthesis in proliferating
cells, PFK-2/FBPase-2 has been proposed as a potential target
for neoplastic treatments. Here we provide evidence that cells
with a low content of fructose-2,6-bisphosphate have a lower
energy status than controls, but they are also less sensitive to
oxidative stress. This feature is related to the activation of the
oxidative branch of the pentose phosphate pathway and the
increased production of NADPH. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Fru-2,6-P2 is a potent allosteric stimulator of 6-phospho-
fructokinase-1 and an inhibitor of fructose-1,6-bisphospha-
tase, key enzymes of the F6P/fructose-1,6-bisphosphate cycle
[1^3]. The synthesis and degradation of Fru-2,6-P2 are cata-
lysed by the bifunctional enzyme PFK-2/FBPase-2. The intra-
cellular concentration of Fru-2,6-P2 depends on the balance
between kinase and phosphatase activities, which, in turn, are
regulated by allosteric e¡ectors, phosphorylation/dephosphor-
ylation processes and by regulation of its gene expression.
Consequently, PFK-2/FBPase-2 is a switch between glycolysis
and gluconeogenesis in mammalian liver and contributes to
the regulation of glycolytic £ux in extrahepatic tissues [1^3].
An increase in Fru-2,6-P2 concentration in growing cells
activates glycolysis and correlates with an enhancement of
PFK-2/FBPase-2 expression and activity [4^8]. Transforma-
tion of chick embryo ¢broblasts by retrovirus carrying either
the v-src or v-fps oncogene induced Fru-2,6-P2 synthesis and
increased glycolytic £ux and cell proliferation [5]. Addition-
ally, the modulation of PFK-2/FBPase-2 expression by
growth factors is concomitant with their mitogenic response
[4]. Recent results [9,10] indicate that changes in Fru-2,6-P2
content may a¡ect a wide diversity of metabolic processes.
Durante et al. reported an enhancement of the apoptosis in-
duced by serum withdrawal in Rat-1 ¢broblasts overexpress-
ing the kinase domain of PFK-2/FBPase-2 [10]. Chesney et al.
identi¢ed an inducible regulatory PFK-2/FBPase-2 isoenzyme
constitutively expressed in several human cancer cell lines and
required for tumour cell growth [9]. Inhibition of inducible
PFK-2 protein expression decreased the intracellular levels
of PRPP, a product of the PPP and a precursor for nucleic
acid biosynthesis. This observation suggested that the Fru-2,6-
P2 regulation of £ux through PFK-1 may a¡ect the non-oxi-
dative PPP [11,12], which is the main source of ribose 5-P in
proliferating cells [13^15]. Moreover, the pentoses cycle con-
tributes to the control of glucose metabolism and provides
cells with NADPH for proliferation [16]. These functions
may also be altered by changes in Fru-2,6-P2 content. To
evaluate the role of PPP in cells with a low Fru-2,6-P2 con-
tent, we measured the activities of the main controlling en-
zymes and the £ux through this metabolic pathway in trans-
fected cells overexpressing FBPase-2 (pFBPase-2 cells). Since
changes in the oxidative PPP may a¡ect the reduction power
of cells, we also measured their sensitivity to the oxidative
stress induced by hydrogen peroxide.
2. Materials and methods
2.1. Chemicals
Dulbecco’s modi¢ed Eagle’s medium (DMEM) and foetal calf se-
rum (FCS) were obtained from Biological Industries (Kibbutz Reit,
Haewek, Israel). Annexin V/FITC was purchased by Bender MedSys-
tems (Vienna, Austria). Enzymes and biochemical reagents were ob-
tained from Boehringer Mannheim (Mannheim, Germany) or Sigma
Chemical (St. Louis, MO, USA).
2.2. Cell transfections and measurement of culture metabolites
Fru-2,6-P2 defective cells were obtained by stable transfection of a
plasmid containing a truncated construction of the rat liver PFK-2/
FBPase-2 enzyme with only the FBPase-2 domain, into a mink lung
epithelial cell line Mv1Lu (CCL-64, American Type Culture Collec-
tion), as previously described [17]. Control cells were transfected with
the empty pcDNA3 vector.
Cells were maintained in DMEM, supplemented with 10% (v/v)
FCS, 100 U/ml of penicillin, 100 Wg/ml of streptomycin and 400 Wg/
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ml of G418 in 100 mm culture dishes (TPP) [17]. To measure heat
production and metabolite production, cell suspensions attached to
microcarriers were used. For a 100 ml culture, approximately
3U107 cells were added to 0.3 g (dry weight) of pre-swollen Cytodex
1 microcarriers (Pharmacia Biotech). Cell concentrations were deter-
mined by a cell counter (Coulter Electronics, UK). To achieve a
maximum yield of cells attached to microcarriers, the cultures were
stirred for 5 min every 30 min. After 4 h, the medium was changed
and the cultures were stirred continuously at 60 rpm. Microcarrier
cultures were incubated for up to 48 h. Before each determination,
cells attached to microcarriers were rinsed and suspended in Krebs
bicarbonate bu¡er containing 10 mM glucose, 10 mM HEPES, 2.5
mM CaCl2, and 2% BSA. Cell suspensions were incubated in glass
vials for 30 min at 37‡C using an orbital shaking bath, and after-
wards, samples for metabolite determination collected in duplicate
at 0, 1.5 and 3 h. ATP and lactate were measured spectrophotometri-
cally in neutralised perchloric extracts using standard enzymatic meth-
ods [4,18,19]. Protein concentration was determined by the Bio-Rad
assay. Fru-2,6-P2 was determined in supernatants by its ability to
activate pyrophosphate-dependent 6-phosphofructo-1-kinase from po-
tato tubers as described elsewhere [20].
2.3. Heat production
To measure heat production, 2.7 ml of the microcarrier suspension
(105 cells/ml) was introduced into each measurement vessel of a Ther-
mal Activity Monitor (LKB-Thermometric AB, Ja«rfalla, Sweden)
thermostatted at 37‡C, as previously described [21]. The air remaining
in the vessels (0.8 ml) and the stirring at 120 rpm provided aerobic
conditions during the measurements. The resulting power^time curves
indicate the heat evolved from the metabolic activity of cell suspen-
sions.
2.4. Measurement of PPP £ux, enzyme activities, and
NADPH/NADP ratio
Mv1Lu cells were scraped into a medium composed of 20 mM Tris^
HCl, 1 mM dithiothreitol (DTT), 1 mM EDTA, 0.2 mM phenyl-
methanesulfonyl £uoride (PMSF), 0.2 g/l Triton X-100 and 0.2 g/l
sodium deoxycholate, at pH 7.5. The cell extracts were further ho-
mogenised in an ultrasound bath (Branson) for 6 min at 0‡C. The
enzymes were partially puri¢ed by ultracentrifugation at 140 000Ug
and 4‡C. G6PDH activity was assayed by measuring the rate of
NADPH production from 0.5 mM NADP and 2 mM Gluc-6P at
pH 7.6 [22]. TK was assayed by measuring the rate of NADH con-
sumption from 0.2 mM NADH, 5 mM MgCl2, 0.1 mM TPP, 2 mM
ribose-5-phosphate and 1 mM xylulose-5-phosphate, at pH 7.6 [23].
Metabolic £ux through the PPP was determined by measuring the rate
of NADPH production from 1 mM NADP, 5 mM MgCl2, 0.2 mM
TPP, 4 mM ribose-5-phosphate and 2 mM xylulose-5-phosphate, at
pH 7.6.
Alkaline extraction of cells was performed with 0.5% Nonidet P-40
bu¡er containing KOH at pH 9, as previously described [16]. The cell
lysates were centrifuged at 3000 rpm for 5 min at 4‡C. The super-
natants were immediately ¢ltered through 10 000 NMWL Ultrafree-
MC centrifugal ¢lter units (Millipore), collected and stored at 320‡C.
Reverse-phase HPLC was performed with a C-18 (25U0.46 cm) an-
alytical column (Tracer) on a Perkin-Elmer HPLC. The mobile phase
and the chromatographic conditions were the same as reported in [16].
Retention times and peak areas were monitored at 254 nm with an
UV detector, and analysed with Turbochrom Navigator software
(Perkin-Elmer). NADPH and NADP standards were dissolved in
extraction bu¡er and immediately injected in the HPLC instrument.
2.5. Flow cytometric analysis
For synchronisation, Mv1Lu cells were cultured in DMEM supple-
mented with 10% FCS for 4 days, up to con£uence. After this period,
cells were harvested, countered and plated (250 000 cells) into 60 mm
dishes to start the experiment. After 48 h, di¡erent amounts of hydro-
gen peroxide were added. 24 h later cells were washed twice in PBS
and once in binding bu¡er composed of 140 mM NaCl, 10 mM
HEPES and 2.5 mM CaCl2, at pH 7.4. Then, cells were stained
with 1 Wl/ml annexin V/FITC and 0.5 Wg/ml propidium iodide for
30 min at room temperature in the dark. Stained cells were analysed
using a FACSCalibur cytometer and the CellQuest software (Becton
Dickinson, CA, USA). Apoptosis was analysed using the MODFIT
program (Becton Dickinson, CA, USA).
2.6. Data analysis
Results are shown as mean þ S.E.M. of the values obtained from
the indicated number of experiments. Di¡erences between groups were
tested by ANOVA and the appropriate a priori contrast methods and
were considered to be statistically signi¢cant at P6 0.05.
3. Results
Metabolic activity, as assessed by microcalorimetry, and
energy status of cells were analysed in cultures of transfected
cells adhered to microcarriers. Our measurements were in
good agreement with those previously reported by Perez et
al. [17] for the same clones. Brie£y, the contents of Fru-2,6-
P2 of control and FBPase-2 cells were 23.6 þ 4 pmol/mg pro-
tein and 5.5 þ 3 pmol/mg protein, respectively. Cells overex-
pressing FBPase-2 showed a 22% reduction in metabolic ac-
tivity and a 26% reduction in lactate production. The ATP
content of FBPase-2 cells was also reduced by 20%.
As a consequence of these metabolic alterations FBPase-2
cells accumulate hexoses-P and reduce trioses-P [17]. These
changes in the glycolytic metabolite concentrations could
drive the activation of the PPP as an alternative metabolic
pathway to provide substrate for the lower part of glycolysis.
To assess this assumption, we evaluated the activity of
G6PDH (Table 1) as the main rate-limiting enzyme of the
PPP [16]. Results shown in Table 1 indicate that G6PDH
activity, and consequently the oxidative £ux of PPP, was high-
er in cells with a low content of Fru-2,6-P2 than in control
cells. The PPP may produce precursors for nucleic acid bio-
synthesis or it may generate glycolytic intermediates through
TK activation and contribute to energy production [16]. To
ascertain this possibility we evaluated TK activity, as well as
the maximal capacity of pentoses cycle to convert xylulose-5-
phosphate and ribose-5-phosphate into G3P and F6P. F6P
can be isomerised to Gluc-6P and re-enter the cycle through
its oxidative branch. Results shown in Table 1 indicate that
both TK activity and PPP £ux were higher in pFBPase-2 cells
than in control cells.
G6PDH is the main source of NADPH utilised in redox
regulation [16] and the activation of this enzyme supplies
pFBPase-2 cells with extra NADPH and reduction power
[24]. The ratio NADPH/NADP measured by HPLC was
20% higher in cells overexpressing FBPase-2 than in control
cells (Table 1).
To ascertain the e¡ect of these changes on the sensitivity to
oxidative stress, exponentially growing cells were incubated
Table 1
E¡ect of overexpression of the bisphosphatase domain of PFK-2/
FBPase-2 on G6PDH and TK activities, and £ux through the PPP
Control pFBPase-2
G6PDH 297 þ 29 412 þ 9**
mU/mg protein (4) (4)
NADPH/NADP 0.55 þ 0.02 0.64 þ 0.03**
(4) (4)
TK 22.7 þ 0.9 27.7 þ 0.5**
mU/mg protein (4) (4)
Flux 2.54 þ 0.24 3.58 þ 0.24*
mU/mg protein (4) (4)
Cells were incubated with DMEM supplemented with 10% FCS.
G6PDH and TK activities were assayed as described in Section 2.
Results are the mean þ S.E.M. from four di¡erent experiments, each
in duplicate. Statistically signi¢cant di¡erences P6 0.05 and
P6 0.01 vs. control cells are indicated by * and **, respectively.
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for 24 h in the presence of increasing amounts of hydrogen
peroxide and analysed by £ow cytometry. Even in the absence
of H2O2, apoptosis was lower for pFBPase-2 cells than for
control cells. These di¡erences were ampli¢ed in the presence
of increasing amounts of hydrogen peroxide (Fig. 1). Consis-
tent with these ¢ndings, cells containing the lowest Fru-2,6-P2
concentration showed a lower extent of membrane blebbing
and chromatin condensation in the presence of hydrogen per-
oxide (data not shown).
4. Discussion
4.1. Higher activity of PPP in FBPase-2 cells
These results indicate a signi¢cant decrease (20%) in the
energy status of Fru-2,6-P2 defective cells, probably as a con-
sequence of a reduction of the glycolytic rate [17]. Energy
equilibrium implies that metabolic £uxes are regulated to bal-
ance the ATP production and consumption, either by reduc-
ing active processes, for instance biosynthesis and transport,
or by increasing other metabolic pathways [17].
Results shown in Table 1 indicate an enhancement of the
oxidative PPP, probably associated with the accumulation of
hexoses-6-P observed in pFBPase-2 cells [17]. Activation of
G6PDH increases intracellular redox level and provides pen-
toses-5-P. These may be transformed into glycolytic metabo-
lites by TK, or into precursors for biosynthesis by PRPP
synthase [11,12,16]. The higher capacity of pFBPase-2 cells
to convert ribose-5-P into glycolytic metabolites (Table 1)
suggests that PPP may be activated in response to a demand
for energy, supplying substrate for glycolysis rather than pro-
viding precursors for biosynthesis. However, conversion of
Gluc-6P into trioses-phosphate through the PPP means to
lose one carbon atom as CO2 for each Gluc-6P entering the
pathway, which is a less e⁄cient way than glycolysis [11,12].
4.2. Lower sensitivity of pFBPase-2 transfectants to oxidative
stress
We attempted to assess whether pFBPase-2 cells derived
advantage from the enhanced PPP £ux since the extra
NADPH produced by the activation of G6PDH could in-
crease resistance of such cells to oxidative stress [16,24,25].
Thus, using male mouse embryonic stem cells, in which
G6PDH gene was disrupted, it was demonstrated that this
enzyme is essential to protect cells against oxidative stress
[26]. Moreover, the clones in which the activity of this enzyme
was undetectable were extremely sensitive to H2O2. Similar
results were recently obtained using a G6PDH-de¢cient cell
line [27].
The results shown in Table 1 and Fig. 1 indicate that cells
with a low content of Fru-2,6-P2 increased their reduction
power and resistance to oxidative insult, which is consistent
with the increased G6PDH activity and NADPH production.
Reciprocally, these results suggest that overproduction of Fru-
2,6-P2 may have the opposite e¡ect: an enhancement of the
glycolytic rate and a reduction of the G6P concentration,
which would limit the £ux through G6PDH and NADPH
production. The concomitant loss of reduction power would
render these cells more susceptible to induced apoptosis [10].
Moreover, biosynthesis depends on the rate of NADPH pro-
duction [16,27] and its restriction could be a limiting factor for
growth of cells with a high content of Fru-2,6-P2 [10].
In conclusion, these results show that a low concentration
of Fru-2,6-P2 reduced energy production, which was partly
compensated by enhancing the £ux through PPP. The activa-
tion of G6PDH provided pFBPase-2 cells with extra reduction
power, which increased their resistance against oxidative
stress.
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